Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Bioton stock price, quote, forecast and news

BIO.WA
PLBIOTN00029
A0D9SD

Price

3.49 PLN
Today +/-
+0 PLN
Today %
+0 %
P

Bioton Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bioton, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bioton from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bioton’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bioton. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bioton’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bioton’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bioton’s growth potential.

Bioton Revenue, EBIT and net profit per share

DateBioton RevenueBioton EBITBioton Net Income
2023181.64 M PLN13.81 M PLN2.28 M PLN
2022233.16 M PLN27.93 M PLN1.42 M PLN
2021163.03 M PLN15.96 M PLN2.88 M PLN
2020221.79 M PLN30.24 M PLN33.92 M PLN
2019202.03 M PLN-71.22 M PLN-126.69 M PLN
2018241.17 M PLN-50.52 M PLN26.27 M PLN
2017361.65 M PLN2.75 M PLN-20.13 M PLN
2016277.61 M PLN-10.83 M PLN-28.57 M PLN
2015332.56 M PLN11.96 M PLN-522.86 M PLN
2014377.3 M PLN21.77 M PLN3.68 M PLN
2013340.4 M PLN8.8 M PLN-6.4 M PLN
2012406.3 M PLN66.5 M PLN37.8 M PLN
2011289 M PLN-54.6 M PLN-78.9 M PLN
2010378.6 M PLN48 M PLN117.2 M PLN
2009286.2 M PLN-320.4 M PLN-546.7 M PLN
2008293.5 M PLN-32.1 M PLN-218.9 M PLN
2007270.9 M PLN100.7 M PLN28.2 M PLN
2006215.5 M PLN74.9 M PLN93.8 M PLN
2005151.6 M PLN26.2 M PLN19.4 M PLN
2004128.8 M PLN16.7 M PLN5.8 M PLN

Bioton Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M PLN)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M PLN)EBIT (M PLN)EBIT MARGIN (%)NET INCOME (M PLN)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
8891119128151215270293286378289406340377332277361241202221163233181
-3.4130.777.5617.9742.3825.588.52-2.3932.17-23.5440.48-16.2610.88-11.94-16.5730.32-33.24-16.189.41-26.2442.94-22.32
29.5537.3646.2245.3170.8661.8654.8144.0338.8156.0835.2952.4642.6541.9148.1949.8251.5248.1350.5047.0647.8540.7739.78
26345558107133148129111212102213145158160138186116102104789572
-9417162674100-32-32048-546682111-102-50-7130152713
-10.234.4014.2912.5017.2234.4237.04-10.92-111.8912.70-18.6916.262.355.573.31-3.610.55-20.75-35.1513.579.2011.597.18
-10275199328-218-546117-7837-63-522-28-2026-12633212
--120.00250.00-28.57280.00389.47-69.89-878.57150.46-121.43-166.67-147.44-116.22-150.00-17,500.00-94.64-28.57-230.00-584.62-126.19-93.94-50.00100.00
12.912.912.915.322.724.72730.442.953.256.271.584.585.8685.8685.8685.8685.8685.8685.8685.8685.8685.86
-----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Bioton Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bioton is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M PLN)RECEIVABLES (M PLN)OTHER REC. (M PLN)INVENTORIES (M PLN)OTHER CURRENT LIAB. (M PLN)CURRENT ASSETS (M PLN)TANGIBLE ASSETS (M PLN)LONG-T. INVEST. (M PLN)LONG-T. REC. (M PLN)INTANGIBLE ASSETS (M PLN)GOODWILL (M PLN)OTHER NON-CURRENT ASSETS (M PLN)NON-CURRENT ASSETS (M PLN)TOTAL ASSETS (M PLN)LIABILITIESCOMMON STOCK (M PLN)ADDITIONAL PAID-IN CAPITAL (M PLN)RETAINED EARNINGS (M PLN)OTHER EQUITY (M PLN)UNREAL. GAINS/LOSSES (M PLN)EQUITY (M PLN)LIABILITIES (M PLN)PROVISIONS (M PLN)OTHER SHORT-TERM LIAB. (M PLN)SHORT-TERM DEBTS (M PLN)LONG-TERM DEBT PORTION (M PLN)SHORT-TERM REC. (M PLN)LONG-T. LIAB. (M PLN)DEFERRED TAXES (M PLN)OTHER LIAB. (M PLN)LONG-T. LIABILITIES (M PLN)DEBT (M PLN)TOTAL CAPITAL (M PLN)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Bioton provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bioton's financial health and stability.

Assets

Bioton's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bioton must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bioton after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bioton's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M PLN)DEPRECIATION (M PLN)DEFERRED TAXES (M PLN)CHANGES IN WORKING CAPITAL (M PLN)NON-CASH ITEM (M PLN)PAID INTEREST (M PLN)PAID TAXES (M PLN)NET CASH FLOW FROM OPERATING ACTIVITIES (M PLN)CAPITAL EXPENDITURES (M PLN)CASH FLOW FROM INVESTING ACTIVITIES (M PLN)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M PLN)INTEREST INCOME AND EXPENSES (M PLN)NET DEBT CHANGE (M PLN)NET CHANGE IN EQUITY (M PLN)CASH FLOW FROM FINANCING ACTIVITIES (M PLN)CASH FLOW FROM OTHER FINANCING ACTIVITIES (PLN)TOTAL DIVIDENDS PAID (M PLN)NET CHANGE IN CASH FLOW (M PLN)FREE CASH FLOW (M PLN)SHARE-BASED COMPENSATION (M PLN)
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-10275199226-223-599110-8336-63-520-28-2026-1263321
1512161691320233138373630333735332932313134
0000000000000000000000
-7-2-28-43-25-34-71133-10-11038240-14-66-10-1530-7-30-308
41232-8223103499-1121-101619574263-581486211
52332382923910191513971066336
0000387100-3024531420001
113-2-175-10037-8027-22144804124231274641556
-13-5-5-17-36-191-196-197-103-45-87-107-61-27-28-24-17-43-53-4-12-29
-223-4-21-68-389-320-289-12958-97-102-57-5-412-937-53-4-4-29
-991-3-32-198-124-92-26103-94321-13268800080
0000000000000000000000
27-148-159030448-221-7276-10-17-152539-33-8912-21-10-19
0008439458024043501700000000000
21-1656547454301266204-8285-24-36-291531-43-966-22-14-26
-5.00-2.00-3.00-3.00-2.00-4.00-2.00-22.00-9.00-10.00-9.00-14.00-18.00-13.00-9.00-7.00-10.00-6.00-6.00-1.00-3.00-6.00
0000000000000000000000
00-126-1654-1914-63-3417-146-157-51-30015-130
-11.87.3-7.5-35.4-30.4-202-196.9-159.6-183.3-17.9-109.837.318.514.04-4.53-1.27-16.16-15.57-6.7537.27-7.3726.5
0000000000000000000000

Bioton stock margins

The Bioton margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bioton. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bioton.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bioton's sales revenue. A higher gross margin percentage indicates that the Bioton retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bioton's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bioton's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bioton's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bioton. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bioton's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bioton Margin History

Bioton Gross marginBioton Profit marginBioton EBIT marginBioton Profit margin
202340.11 %7.61 %1.25 %
202241.07 %11.98 %0.61 %
202148.06 %9.79 %1.77 %
202047.24 %13.63 %15.29 %
201950.65 %-35.25 %-62.71 %
201848.15 %-20.95 %10.89 %
201751.51 %0.76 %-5.57 %
201649.72 %-3.9 %-10.29 %
201548.12 %3.6 %-157.22 %
201441.96 %5.77 %0.97 %
201342.83 %2.59 %-1.88 %
201252.55 %16.37 %9.3 %
201135.5 %-18.89 %-27.3 %
201056.13 %12.68 %30.96 %
200938.89 %-111.95 %-191.02 %
200843.99 %-10.94 %-74.58 %
200754.63 %37.17 %10.41 %
200662.09 %34.76 %43.53 %
200570.91 %17.28 %12.8 %
200445.73 %12.97 %4.5 %

Bioton Stock Sales Revenue, EBIT, Earnings per Share

The Bioton earnings per share therefore indicates how much revenue Bioton has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bioton earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bioton's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bioton’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bioton's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bioton Revenue, EBIT and net profit per share

DateBioton Sales per ShareBioton EBIT per shareBioton Earnings per Share
20232.12 PLN0.16 PLN0.03 PLN
20222.72 PLN0.33 PLN0.02 PLN
20211.9 PLN0.19 PLN0.03 PLN
20202.58 PLN0.35 PLN0.4 PLN
20192.35 PLN-0.83 PLN-1.48 PLN
20182.81 PLN-0.59 PLN0.31 PLN
20174.21 PLN0.03 PLN-0.23 PLN
20163.23 PLN-0.13 PLN-0.33 PLN
20153.87 PLN0.14 PLN-6.09 PLN
20144.39 PLN0.25 PLN0.04 PLN
20134.03 PLN0.1 PLN-0.08 PLN
20125.68 PLN0.93 PLN0.53 PLN
20115.14 PLN-0.97 PLN-1.4 PLN
20107.12 PLN0.9 PLN2.2 PLN
20096.67 PLN-7.47 PLN-12.74 PLN
20089.65 PLN-1.06 PLN-7.2 PLN
200710.03 PLN3.73 PLN1.04 PLN
20068.72 PLN3.03 PLN3.8 PLN
20056.68 PLN1.15 PLN0.85 PLN
20048.42 PLN1.09 PLN0.38 PLN

Bioton business model

Bioton SA is a leading Polish biotechnology company specializing in the development of innovative drugs, diagnostics, and medical devices. The company was founded in 1989 and has since achieved remarkable success. Bioton is headquartered in Poland and employs approximately 1000 people worldwide. The company is listed on the Warsaw Stock Exchange and is supported by renowned investors. Business model Bioton operates various business divisions, including research and development, production, sales, as well as marketing and distribution. The company collaborates closely with leading academic institutions and research organizations and invests significant resources in the development of new groundbreaking technologies and products. The company's products and services are distributed and used in over 60 countries worldwide. Divisions Bioton is divided into three main business sectors, including biopharmaceuticals, diagnostics, and medical devices. Biopharmaceuticals Bioton is known for its biopharmaceuticals, particularly insulin and insulin analogs. Insulin is a hormone produced by the body to regulate blood sugar levels. Bioton offers various insulin products, including human insulin, insulin glargine, and insulin aspart. These products are approved for the treatment of diabetes mellitus and are distributed in over 50 countries worldwide. Diagnostics Bioton is also involved in the development and production of diagnostics. The company offers various testing systems for the diagnosis of infectious diseases, allergies, and autoimmune diseases. The product line also includes in vitro diagnostics that are used for medical therapy monitoring and disease detection. Medical devices Bioton also manufactures and distributes medical devices such as insulin pumps and blood glucose meters. These devices are designed for people with diabetes and assist in accurate insulin dosing and blood sugar level monitoring. Products In addition to insulin and insulin analogs, Bioton also produces a wide range of other drugs, including growth hormones, as well as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are used for the treatment of infertility. Bioton is also involved in the development of novel technologies such as RNA interference (RNAi) and genomic research. The company invests significantly in innovative research projects aimed at the development of groundbreaking drugs and therapies. In conclusion, Bioton SA is a highly innovative biotechnology company with a wide range of products and a focus on research and development. The company operates in the global market and collaborates closely with renowned institutions and research organizations. Bioton's business model is based on the development of innovative technologies and products aimed at improving the quality of life for people worldwide. Bioton is one of the most popular companies on Eulerpool.com.

Bioton SWOT Analysis

Strengths

Bioton SA has a strong market presence and brand recognition in the pharmaceutical industry. The company's extensive experience and expertise in the development and manufacturing of biotechnology and pharmaceutical products give it a competitive advantage. Additionally, Bioton SA has a diverse product portfolio, catering to various medical needs.

Weaknesses

One weakness of Bioton SA is its dependence on a limited number of key products. This exposes the company to market fluctuations and risks associated with product failures. Bioton SA may also face challenges in terms of intellectual property protection and maintaining a reliable supply chain.

Opportunities

There are several opportunities for Bioton SA to explore. The increasing global demand for biotechnology and pharmaceutical products presents a growth opportunity for the company. Bioton SA could also consider expanding its product offerings or entering new markets to diversify its revenue streams. Collaborations and partnerships with other industry players could further enhance Bioton SA's market position.

Threats

Bioton SA faces threats from intense competition in the pharmaceutical industry. The presence of both established multinational companies and emerging biotech firms can pose challenges to Bioton SA's market share. Additionally, regulatory changes and stringent compliance requirements may impact the company's operations and product development processes. Economic uncertainties and geopolitical factors can also influence Bioton SA's business environment.

Bioton historical P/E ratio, EBIT, and P/S ratio.

Bioton shares outstanding

The number of shares was Bioton in 2023 — This indicates how many shares 85.864 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bioton earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bioton's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bioton’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bioton's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bioton Stock splits

In Bioton's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Bioton.

Bioton latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20101.41 PLN1.9 PLN (34.37 %)2010 Q4
9/30/2010-0.1 PLN-0.2 PLN (-98.02 %)2010 Q3
12/31/2009-0.2 PLN-8 PLN (-3,860.4 %)2009 Q4
9/30/2009-0.2 PLN-0.2 PLN (0.99 %)2009 Q3
12/31/20070.4 PLN0.1 PLN (-75.25 %)2007 Q4
9/30/20070.71 PLN0.4 PLN (-43.42 %)2007 Q3
6/30/20070.71 PLN2.1 PLN (197.03 %)2007 Q2
3/31/20070.71 PLN0.4 PLN (-43.42 %)2007 Q1
12/31/20060.51 PLN2 PLN (296.04 %)2006 Q4
1

Bioton list of shareholders

%
Name
Stocks
Change
Date
9.88 % Troqueera Enterprises, Ltd.8,480,57002/22/2024
7.16 % Basolma Holding Ltd6,151,85202/22/2024
6.00 % Ais Investment 2 Sp. z.o.o.5,151,85202/22/2024
5.00 % Cui (Wenjun)4,293,21002/22/2024
31.65 % Yifan Pharmaceutical Co Ltd27,175,70802/22/2024
0.29 % Dimensional Fund Advisors, L.P.245,30401/31/2024
0.11 % Polunin Capital Partners Limited96,588012/31/2022
0.02 % Dimensional Fund Advisors, Ltd.20,10801/31/2024
0.00 % State Street Global Advisors (US)8361322/29/2024
1

Bioton Executives and Management Board

Mr. Jeremy Launders
Bioton President of the Management Board
Compensation 1.82 M PLN
Mr. Adam Polonek
Bioton Member of the Management Board
Compensation 861,000 PLN
Mr. Nicola Cadei
Bioton Chairman of the Supervisory Board (since 2019)
Compensation 39,000 PLN
Mr. Ramesh Rajentheran
Bioton Vice Chairman of the Supervisory Board (since 2019)
Compensation 36,000 PLN
Mr. Dariusz Trzeciak
Bioton Vice President of the Supervisory Board (since 2013)
Compensation 36,000 PLN
1
2

Most common questions regarding Bioton

What values and corporate philosophy does Bioton represent?

Bioton SA is a leading biotechnology company that represents a strong set of values and corporate philosophy. The company values innovation, research, and development to provide cutting-edge solutions in the field of biotechnology. Bioton SA focuses on providing high-quality healthcare products and services to improve people's lives. With a commitment to excellence and a customer-centric approach, Bioton SA aims to deliver value to its stakeholders. The company's philosophy centers around sustainable growth, ethical practices, and fostering partnerships to drive success. Bioton SA's dedication to scientific advancement and ethical business conduct makes it a trusted name in the biotechnology industry.

In which countries and regions is Bioton primarily present?

Bioton SA is primarily present in Poland, where it is headquartered. Additionally, Bioton SA has a significant presence in the European market, specifically in countries such as Germany, France, and the United Kingdom.

What significant milestones has the company Bioton achieved?

Bioton SA, a leading pharmaceutical company, has achieved remarkable milestones throughout its existence. The company garnered global recognition for its groundbreaking advancements in the field of biotechnology. Bioton SA successfully introduced innovative pharmaceutical products, including insulin and other life-saving medications, revolutionizing the treatment of diabetes and various other medical conditions. Moreover, the company's dedicated research and development efforts have enabled Bioton SA to expand its product portfolio and consistently deliver high-quality therapeutic solutions to meet the growing healthcare needs of patients worldwide. Bioton SA's commitment to excellence and continuous innovation has established it as a prominent leader in the pharmaceutical industry.

What is the history and background of the company Bioton?

Bioton SA is a renowned pharmaceutical company with a rich history and background. Established in 1989, Bioton SA has become a pioneer in the field of biotechnology and specializes in the development, production, and marketing of innovative pharmaceuticals. With its headquarters in Poland, Bioton SA has successfully expanded its operations globally. The company has made significant contributions to the medical industry through its cutting-edge research and development efforts, particularly in the fields of diabetes and human insulin production. Bioton SA continuously strives to provide high-quality products and improve global healthcare standards, solidifying its position as a leading player in the pharmaceutical sector.

Who are the main competitors of Bioton in the market?

The main competitors of Bioton SA in the market are Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, and Merck & Co., Inc.

In which industries is Bioton primarily active?

Bioton SA is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Bioton?

The business model of Bioton SA revolves around the development, manufacturing, and distribution of innovative biopharmaceutical products. Bioton SA specializes in the production of recombinant human insulin and insulin analogs, addressing the needs of diabetic patients worldwide. The company focuses on research and development activities to continuously improve their products and expand their portfolio. Bioton SA strives to provide high-quality and affordable healthcare solutions, catering to the growing demand for diabetes treatment options. With their strong commitment to innovation and patient care, Bioton SA aims to establish itself as a leading player in the biopharmaceutical industry.

What is the P/E ratio of Bioton 2024?

The P/E ratio cannot be calculated for Bioton at the moment.

What is the P/S ratio of Bioton 2024?

The P/S cannot be calculated for Bioton currently.

What is the AlleAktien quality score of Bioton?

The AlleAktien quality score cannot be calculated for Bioton at the moment.

What is the revenue of Bioton 2024?

The revenue cannot currently be calculated for Bioton.

How high is the profit of Bioton 2024?

The profit cannot currently be calculated for Bioton.

What is the business model of Bioton

Bioton SA is a Polish biotechnology company that specializes in the development and production of biotechnological and medical products. The company's business model is focused on advancing innovation and research in biotechnology and producing high-quality products suitable for both the Polish and international markets. The company is divided into three divisions: medicine, agriculture, and industry, each offering its own products and services. In medicine, Bioton SA offers a wide range of products for prevention, diagnosis, and therapy of various diseases, including diagnostic kits, vaccines, and therapeutics. In the agriculture division, the company aims to improve global food production through the development and production of animal feed and biotechnological enzymes, which enhance the nutrition of livestock and increase the nutritional value of meat, milk, and eggs. In the industry division, Bioton SA develops biotechnological enzymes and processes used in the food and beverage industry, as well as other industries such as textiles and paper, to improve production efficiency and product quality. The company emphasizes its strong presence in research and development, with a team of highly qualified scientists and technicians dedicated to researching and developing new products. Bioton SA also invests heavily in collaboration with universities and research institutes to stay at the forefront of technology and drive continuous innovation. Additionally, the company highlights its strong presence in the international market, with branches in several countries in Europe, Asia, and South America. It also operates several subsidiaries specialized in selling and marketing products in specific markets. Overall, Bioton SA's business model is focused on producing high-quality products while promoting the growth and development of the biotechnology industry. The company emphasizes its presence in various industries and markets and its ability to conduct innovation and research at the highest level.

What is the Bioton dividend?

Bioton pays a dividend of 0 PLN distributed over payouts per year.

How often does Bioton pay dividends?

The dividend cannot currently be calculated for Bioton or the company does not pay out a dividend.

What is the Bioton ISIN?

The ISIN of Bioton is PLBIOTN00029.

What is the Bioton WKN?

The WKN of Bioton is A0D9SD.

What is the Bioton ticker?

The ticker of Bioton is BIO.WA.

How much dividend does Bioton pay?

Over the past 12 months, Bioton paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bioton is expected to pay a dividend of 0 PLN.

What is the dividend yield of Bioton?

The current dividend yield of Bioton is .

When does Bioton pay dividends?

Bioton pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bioton?

Bioton paid dividends every year for the past 0 years.

What is the dividend of Bioton?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bioton located?

Bioton is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bioton kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bioton from 8/1/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Bioton pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Bioton in the year 2023?

In the year 2023, Bioton distributed 0 PLN as dividends.

In which currency does Bioton pay out the dividend?

The dividends of Bioton are distributed in PLN.

All fundamentals about Bioton

Our stock analysis for Bioton Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioton Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.